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Abstract
The metabolism of a nitroderivative of acetylsalicylic acid, benzoic acid, 2-(acetyloxy)-3-[(nitrooxy)methyl]phenyl
ester (NCX4016), the lead compound of a new class of NO-releasing non steroidal-antiinflammatory drugs has been
studied in vitro in rat liver subcellular fractions (S 9000×g, microsomes, cytosol). Samples were extracted with
CH3CN (2 vol.) containing 1% H3PO4 (2 M), vortexed for 3 min and then centrifuged for 5 min at 5000 rpm.
Supernatants were diluted with 0.02 M phosphoric acid and analysed by reverse-phase LC. Linearity of calibration
for NCX4016 and metabolites was observed over the range 0.25–50 g/ml with coefficients of determination greater
than 0.9996. Extraction efficiency from spiked liver samples ranged from 85 to 95% for all the analytes. In the S
9000×g fraction, NCX4016 undergoes rapid metabolization, with the formation of salicylic acid (SA) and
[3-(nitrooxymethyl)phenol] (HBN). HBN is then rapidly metabolised to 3-hydroxybenzylalcohol (HBA), and mainly
to a new metabolic species, whose formation takes place specifically in the liver cell cytosol. LC–MS analysis
(electrospray ionisation) of the cytosol extract in negative and positive-ion modes furnished deprotonated [M−H]−
and protonated [M+H]+ molecular ions at m/z 412 and 414, respectively, accompanied by the typical clusters with
sodium. MS/MS analysis in negative-ion mode, by selection and collision of the ion at m/z 412, gave a fragmentation
pattern characterized by the ions at m/z 272 and 254, which allowed to assign the structure of 1-(glutathion-S-
yl)methylene-3-hydroxy-benzene, a conjugated product between GSH and the benzyl carbon atom of HBN. In rat
liver cytosol HBN is completely metabolised to this thioether adduct within 30 min incubation; the process is
enzymatically mediated by GSH transferase and strictly dependent on GSH availability. The relevance of this new
metabolic pathway in NCX4016 detoxification by rat liver is discussed. © 2002 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Benzoic acid, 2-(acetyloxy)-3-[(nitrooxy)meth-
yl]phenyl ester (NCX4016) (Fig. 1), the ni-
troderivative of aspirin, is the lead compound of
a new class of NO-releasing non steroidal anti-in-
flammatory drugs (NO-NSAIDs). In pre-clinical
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studies the drug has been shown to display antiag-
gregatory and antithrombotic activity by a dual
mechanism of action involving inhibition of cy-
clooxygenase (COX) and release of nitric oxide
(NO), the latter acting on guanylate cyclase in
both platelets and vascular smooth muscle cells
[1,2]. The drug was also found to be devoid of
typical toxic effects of COX-1 inhibitors
(NSAIDs) on gastric mucosa also following re-
peated oral administration. This through inhibi-
tion of neutrophil adherence to vascular
endothelium [3]. In addition, recent results indi-
cated that NCX4016 is a powerful agent in im-
proving the post-ischemic ventricular dysfunction
in the rabbit heart [4] and in reducing the infarct
size in rat heart induced by ischemia-reperfusion
[5].
While the pharmacokinetic profile of the drug
following single or repeated oral doses in the rat is
known (no NCX4016 has been detected in
plasma, but only salicylic acid) [2,6], no studies
have been performed on its metabolism in vitro or
in vivo in the animal.
As a first step, to elucidate the metabolic pic-
ture of the drug, in this work we have studied the
in vitro metabolism of NCX4016 by rat liver,
using the combined approach of LC–UV–DAD
and LC–UV–DAD–MS/MS for the identifica-
tion and quantitative determination of metabo-
lites in different hepatic subcellular fractions: S
9000×g supernatant fraction, cytosol (105 000×
g supernatant fraction) and microsomes, with the
final aim to define the key metabolic steps of
biotransformation of the drug and the kinetics of
its metabolization by the liver.
2. Materials and methods
2.1. Chemicals
HPLC-grade and analytical-grade organic sol-
vents were purchased from Merck (Bracco, Milan,
Italy). HPLC-grade water was prepared with a
Milli-Q water purification system. Benzoic acid,
Fig. 1. Structures of NCX4016 and of some postulated metabolic products.
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2-(acetyloxy)-3-[(nitrooxy)methyl]phenyl ester
(NO-ASA; NCX4016) and the NO-ASA metabo-
lites: benzoic acid, 2-(hydroxy)-3-[(ni-
trooxy)methyl]phenyl ester (NCX4023), benzoic
acid, 2-(acetyloxy)-3-(hydroxymethyl)phenyl ester
(NCX4017), benzoic acid, 2-(hydroxy)-3-(hydrox-
ymethyl)phenyl ester (NCX4019) and benzen-
emethanol,3-hydroxy--nitrate (HBN) were
kindly provided by NICOX S.A. (Sophia An-
tipolis, France); benzenemethanol, 3-hydroxy
(HBA), benzoic acid, 3-hydroxy (HBAC), acetyl-
salicylic acid (ASA), SA, glutathione (GSH), sul-
phobromophtalein (SBP) and N-ethylmaleimide
(NEM) were purchased from Fluka Chimica (Mi-
lan, Italy); NADPH and NADH from Roche
(Milan, Italy).
2.2. Apparatus
LC analyses were carried out on a Thermoquest
Surveyor system equipped with a quaternary
pump, a Surveyor UV/VIS Diode Array pro-
grammable detector 6000 LP model, a Surveyor
AS autosampler, a vacuum degasser, and an Xcal-
ibaur software. Separations were done by reverse-
phase elution (Merck Licrosphere RP8 column;
25 cm×4.6 mm i.d.; particle size 5 ) in the
following conditions: gradient elution from 100%
solvent A CH3CN–water–phosphoric acid
(1:9:0.01, v/v/v) to 60% B (CH3CN) in 30 min;
flow rate 1 ml/min; UV–DAD detection (scan
range 200–600 nm; rate 0.5 scan/s). LC–MS ex-
periments were performed on a Finningan MAT
(San Jose`, CA) LCQ Duo Ion Trap mass spec-
trometer operating in atmospheric pressure ioni-
sation fitted with an electrospray ionisation source
(ESI), equipped with an orthogonal sampling
adapter (compatible with non-volatile buffers)
and connected to the LC system. The capillary
temperature and the ionisation voltage were main-
tained at 250 °C and 4.5 kV, respectively. The
mass spectrometer was operated in the negative-
ion and positive-ion modes, with a scan range
from m/z 200 to 600 (scan rate 0.5 scans/s).
Collision induced dissociation (CID) experiments
in negative-ion mode were performed by resonant
excitation by optimisation of the collision energy
to 40%.
2.3. Standard solutions
A stock solution of NCX4016, SA, HBN and
HBA (5 mg/ml for each) was prepared in CH3CN.
This solution was further diluted with CH3CN to
give a series of standards with concentrations of
5, 10, 20, 50, 200, 500 and 1000 g/ml (0.25, 0.5,
1.0, 2.5, 10, 25 and 50 g/ml in the hepatic tissue
samples).
2.4. In itro studies
Male Wistar rats (Charles-River, Calco, LC,
Italy; 22010×g body weight) were maintained
in compliance with the policy on animal care
expressed in the National Research Council guide-
lines (NRC 1985). The animals were housed indi-
vidually in stainless steel cages under standard
conditions (temperature 222 °C; 5010%
relative humidity; artificial light from 06:00 to
20:00 h).
The animals, fasted overnight before experi-
ments, were killed by cervical dislocation; the
livers were immediately perfused with cold NaCl
(0.9%, w/v), excised and minced in cold KCl
(1.15%, w/v) and homogenized in 0.1M phosphate
buffer, pH 7.4. Liver subcellular fractions (9000×
g supernatant fraction, 105 000×g supernatant
fraction and microsomes) were prepared by differ-
ential centrifugation as previously described [7].
The microsomal pellets were washed once by ho-
mogenisation in 1.15% KCl and recentrifuged at
105 000×g.
A volume of 0.05 ml aliquots of NCX4016
working standard (5 mg/ml in CH3CN) were
added to rat liver subcellular fractions equivalent
to 2.5 g of fresh liver tissue. After 5 min preincu-
bation at 37 °C, 0.3 mM MgCl2, 1.5 mM
NADPH, 1.5 mM NADH were added to the
incubation mixture (5 ml final volume). The mix-
tures were incubated in a metabolic shaker for
different time periods up to 180 min. At the end of
each incubation time, 0.5 ml aliquots were ex-
tracted with CH3CN (2 vol.) containing 1% phos-
phoric acid (2 M), vortexed for 5 min and then
centrifuged for 5 min at 5000 rpm. Supernatants
were diluted to 2 ml with 0.02 M phosphoric acid
and 50 l aliquots were submitted to LC analysis.
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In another set of experiments, HBA (5 mg/ml in
CH3CN) was incubated up to 3 h at 37 °C with
rat liver S 9000×g fractions (final concentration
50 g/ml tissue sample) supplemented with 1.5
mM GSH or 1.5 mM NADPH, and HBN (5
mg/ml in CH3CN) with cytosol (final concentra-
tion 50 g/ml tissue sample). In the last case,
incubations were carried out for 90 min in the
presence or in the absence of 5 mM NEM or 2
mM SBP. All the samples were extracted and
processed as above described.
2.5. Method alidation
The calibration lines were constructed by
weighted (1/x) least-square linear regression anal-
ysis of the peak areas of analytes versus the
concentrations. The calibration equation was used
to calculate the concentration of analytes in the
replicated and incubated samples. The precision
and accuracy of the method were determined by
the replicate analysis of S 9000 subcellular frac-
tion samples containing the analytes at concentra-
tions of 0.25, 2.5, 10 and 50 g/ml for NCX4016
and SA and of 0.5, 2.5, 10 and 50 g/ml for HBN
and HBA in the calibration ranges. The accuracy
was determined by calculating the relative error
(RE%) and the precision by the coefficient of
variation (CV%).
2.6. Storage stability
The storage stability of NCX4016, HBN, SA
and HBA in rat liver tissue was studied by repli-
cate analysis of S 9000 fraction extracts contain-
ing known amounts of analytes stored at −20 °C
for 4 weeks at concentrations of 0.5, 10 and 50
g/ml.
3. Results and discussion
3.1. In itro studies
In Fig. 1 are reported the structures of
NCX4016 and of some postulated metabolites of
the drug which could arise from different bio-
transformation pathways involving single or mul-
Fig. 2. HPLC separation of NCX4016 and its metabolites in
liver tissue extracts. (a) Blank tissue (S 9000 g fraction); (b) S
9000 g fraction spiked with 5 g/ml NCX4016, HBN, HBA
and 2.5 g/ml NCX4017, NCX4019, NCX4023, ASA, SA.
tiple hydrolytic cleavage of the different ester
functions in the molecule (acetate, benzoate and
nitrate esters). Firstly we developed a reverse-
phase HPLC method for analysis of all the
metabolites in liver samples. The chromato-
graphic profile reported in Fig. 2b is obtained
from an extract of the native S 9000×g fraction
spiked with a mixture of NCX4016 and metabo-
lites, and shows that the employed gradient elu-
tion efficiently separated all the analytes with no
interference from the blank matrix.
NCX4016 was then incubated with rat liver S
9000×g fraction (the more complete drug
metabolising enzyme system) under aerobic condi-
tions and in the presence of electrogenic cofactors
(NADPH+NADH), and the formation of the
metabolites was monitored by HPLC analysis
with UV–DAD detection at 228 nm at different
incubation times.
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SA, HBN and HBA and an unknown com-
pound with RT 10.15 min were detected, but no
one of the other postulated metabolites. This indi-
cated that the most labile function in the molecule
is the acetate ester (absence of acetylated deriva-
tives NCX4017 and ASA), followed by the ben-
zoate ester (no NCX4023), while the nitrate ester
is more resistant to the enzymatic attack (no
formation of NCX4019 and retention of HBN
species).
The chromatographic profile of the extract rela-
tive to 90 min incubation (Fig. 3a) evidenced that
HBN and HBA are minor metabolic species,
while SA (RT 8.35 min) and the unknown com- Fig. 4. Kinetics of NCX4016 metabolization by rat liver S
9000 g subcellular fraction. S 9000 g fraction equivalent to 2.5
g fresh tissue was incubated with 250 g NCX4016, 1.5 mM
NADPH, 1.5 mM NADH, 0.3 mM MgCl2 (final volume 5
ml). At different incubation times, 0.5 ml aliquots were ex-
tracted and processed as described in Methods. Each value is
the meanS.D. of five independent experiments.
Fig. 3. Metabolization of NCX4016 by different rat liver
subcellular fractions. The LC profiles refer to tissue samples
(equivalent to 2.5 g fresh tissue) incubated for 90 min with 250
g NCX4016, 1.5 mM NADPH, 1.5 mM NADH, 0.3 mM
MgCl2 (final volume 5 ml) and extracted as described in
Methods. In cytosol incubates NADPH, NADH, and MgCl2
were omitted.
pound (RT 10.15 min) are the most abundant.
The kinetics of NCX4016 metabolization deter-
mined by quantitation of the drug and its known
metabolites in S 9000×g samples at different
incubation times (Fig. 4) indicated that ni-
troaspirin undergoes complete biotransformation
to SA and HBN within the first 5 min, due to the
cleavage of the acetate and the benzoate esters.
While SA is a final metabolite (maximal increase
within 5 min and plateau between 5 and 15 min),
HBN is rapidly metabolised to the unknown
metabolic species, whose formation is maximal at
90 min and strictly parallels the kinetics of HBN
disappearance. Only in minimal amount HBN is
converted to HBA.
In order to identify the cellular compartment
and the enzyme system involved, S 9000 was
fractionated into microsomes and cytosol, and
NCX4016 was incubated with both subcellular
fractions for a fixed time period (90 min). The
unknown metabolite is formed in cytosol but not
in microsomes; conversely HBA is absent in cyto-
sol, but present in microsomes as final metabolic
product (Fig. 3).
Hence, the extract from cytosol incubated with
nitroaspirin was analysed by LC coupled to mass
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spectrometry with ES ionisation interface, a soft
ionisation technique which furnishes unequivocal
information on molecular weight. The peak with
RT 10.15 min showed an UV–DAD profile (Fig.
5a insert) typical of a phenol derivative with max
at 276 nm, which was superimposable to those of
HBN or HBA; in the negative-ion mode, it gave a
deprotonated molecular anion at m/z 412, confi-
rmed by the typical clusters with sodium or potas-
sium (Fig. 5b and c) and by the selected ion
chromatogram (SIC) relative to this ionic species
(Fig. 5d).
Molecular weight was confirmed by recording
the mass spectrum in the positive-ion mode (Fig.
6a) which furnished a quasi molecular ion [M+
H]+ at m/z 414 and a cationized molecular ion
[M+Na]+ at m/z 436. Structure elucidation was
achieved by MS/MS experiments in negative-ion
mode, by selection and collision of the ion at m/z
412 (Fig. 6b): the fragmentation pattern, with the
ions at m/z 272 and 254 allowed to assign the
structure of 1-(glutathion-S-yl)methylene-3-hy-
droxy-benzene, a thioether conjugated product
between GSH and the benzyl carbon atom of
Fig. 5. LC–MS analysis of cytosol extract (90 min incubation). (a) LC–UV–DAD profile (insert: UV spectrum of the peak with
R.T. 10.15 min); (b) Total ion current chromatogram (m/z 200–600); (c) negative-ion ESI mass spectrum; (d) selected ion
chromatogram (SIC) of [M−H]− at m/z 412.
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Fig. 6. Positive-ion ESI mass spectrum of the peak with R.T. 10.15 min (a) and CID (collision-induced dissociation) mass spectrum
of the [M−H]− at m/z 412 in negative-ion mode (b).
HBA or HBN. To gain a deeper insight into the
mechanism of its formation, HBA was incubated
with the S 9000×g fraction: no conjugated
metabolite was detected at any observation time,
even in the presence of high concentrations of
GSH (5 mM). As shown in Fig. 7 and Table 1,
the only metabolite which arised from HBA in the
S 9000×g fraction was its oxidation product,
3-hydroxybenzoic acid (HBAC; R.T. 11.52 min),
identified by comparison with the chromato-
graphic properties of the standard. The formation
of the latter compound requires electrogenic co-
factors (NADPH, NADH; i.e. cytochrome P-450
involvement) and proceeds with an extremely low
kinetics (only the 23% of the incubated dose is
oxidized after 3 h incubation). This unequivocally
excludes HBA as direct precursor of the thioether
metabolite and point to a role for HBN. Incuba-
tion of HBN with rat liver cytosol (Table 2)
demonstrates that the compound is completely
metabolised to the thioether derivative within 30
min: the process is enzymatically mediated, since
no metabolite is observed in inactivated cytosol
(by heating at 100 °C), even in the presence of
high GSH concentrations. The conjugation pro-
cess is inhibited by NEM (a well known alkylating
agent for thiols) or by SBP (a typical inhibitor of
GSH-transferases) to confirm the strict depen-
dence on GSH availability and on an enzyme
system belonging to the family of GSH-S-
tranferases.
Hence the metabolite arises from HBN through
the nucleophilic displacement by GSH of the eas-
ily leaving ONO2− group from the highly elec-
trophilic benzyl carbon atom. The poorer leaving
ability of the primary OH group in HBA explains
why this compound does not react with GSH and
it is not the precursor of the thioether.
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This new metabolic pathway, which seems spe-
cifically linked to the cytosol compartment of the
liver cell, and to the chemical structure of the
spacer of NCX4016, is quite unusual and can be
considered alternative to that commonly proposed
for organic nitrates used in cardiovascular therapy
(i.e. nitroglycerin), where the nitrate ester enzy-
matically trans-esterificate GSH with formation
of GSNO2 and of the corresponding alcohol [8].
On the other hand, HBA from NCX4016 in S
9000×g fraction or microsomes may arise from
this conventional metabolic pathway or from a
cytochrome P-450 mediated denitration process
[9].
3.2. Linearity of calibration
S 9000×g fraction samples spiked with the
analytes to give concentrations of 0.25, 0.5, 1.0,
Table 1
Time-course of HBA metabolization by S 9000×g fraction
Incubation time 3-Hydroxybenzoic acid formation
(min)
nmoles/g tissue% of the incubated
dose
15 – –
30 10.11.22.50.6
60 28.11.87.10.9
12.41.390 49.62.6
120 74.84.218.72.1
94.13.6180 23.51.8
S 9000×g fraction equivalent to 2.5 g fresh tissue was incu-
bated with 250 g HBA, 1.5 mM NADPH, 1.5 mM NADH,
0.3 mM MgCl2 (final volume 5 ml). At different incubation
times, 0.5 ml aliquots were extracted and processed as de-
scribed in Section 2 (final volume 2.0 ml). The formation of
HBAC was determined by measuring the disappearance of
HBA. Each value is the meanS.D. of five independent
experiments.
Fig. 7. LC–UV–DAD profiles of S 9000 g subcellular fraction
incubated with HBA.S 9000 g fraction equivalent to 2.5 g fresh
tissue was incubated with 250 g HBA, 1.5 mM NADPH, 1.5
mM NADH, 0.3 mM MgCl2 (final volume 5 ml). At different
incubation times, 0.5 ml aliquots were extracted and processed
as described in Methods. Each value is the meanS.D. of five
independent experiments.
2.5, 10, 25 and 50 g/ml for NCX4016 and SA
and of 0.5, 1.0, 2.5, 10, 25 and 50 g/ml for HBN
and HBA were analysed. For each compound the
standard response was linear over the entire cali-
bration range, with correlation coefficients greater
than 0.9995. The equations of the calibration lines
were as follows: y=1407.1x+25.6 (r2=0.9996)
for NCX4016; y=571.5x+14.6 (r2=0.9999) for
HBN; y=493x+126 (r2=0.9998) for HBA; y=
1109x−403 (r2=0.9996) for SA.
3.3. Precision and accuracy
The intra-assay precision and accuracy of the
method were determined by analysing six repli-
cates at four concentration levels for each com-
pound, and the relative data are summarized in
Table 3. The RE of NCX4016 and SA at 0.25
g/ml were −10 and −5.2%, respectively, and
those of HBN and HBA at 0.5 g/ml were −4.0
and +3.0%. The CV of NCX4016 and SA at 0.25
g/ml were 6.48 and 7.80%, respectively, and
those of HBN and HBA at 0.5 g/ml were 4.95
and 8.28%. Hence the limits of quantitation of
NCX4016, SA, HBN and HBA were determined
as 0.25, 0.25, 0.5 and 0.5 g/ml, respectively, as
the lowest concentrations that can be determined
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with an acceptable accuracy of 20% and a
precision below 20%.
The intermediate precision and accuracy were
determined at the same concentrations (3 days).
The accuracy for all the analytes (Table 4) ranged
from −5.2 to +4.0% of nominated concentra-
tions with precision ranging from 1.75 to 7.82%
over the concentration ranges evaluated.
3.4. Extraction efficiency and storage stability
The recovery test was performed by comparing
the response of extracted samples spiked with
NCX4016 and metabolites before extraction with
that of extracted blank samples spiked just before
injection (to compensate for any effect due to the
matrix). Percentage recoveries, determined at the
two extremes of the calibration ranges (n=6
each) were satisfactory, ranging from 85 to 95%
for all the compounds (data not shown). The
storage stability of NCX 4016 and its metabolites
in rat liver tissue extracts was determined at
−20 °C using S 9000×g fraction samples spiked
with the analytes (NCX4016, SA, HBN, HBA) at
0.5, 2.5 and 50 g/ml (n=3). The recoveries were
from 92.4 to 102.7% for all the analytes, to indi-
cate that they were stable for at least 4 weeks in
tissue extracts when stored at −20 °C.
4. Conclusions
A reliable HPLC assay for the simultaneous
determination of NCX 4016 and its metabolites in
liver tissue has been developed, which provides
satisfactory accuracy and precision for all the
analytes. The method has been successfully ap-
plied to the study of the in vitro metabolism of
the drug by rat liver, to get an insight into the key
metabolic steps of its hepatic biotransformation
and detoxification and seems to be applicable also
to the study of the in vivo metabolism of the
drug. Although preliminary, the results of this
study, in particular the formation of the glu-
tathione conjugate, can explain some hardly rec-
oncilable findings raised by previous
pharmacokinetics studies of others and us [2,6,10]
after oral administration of the drug in the rat
– low or none systemic bioavailablity of the
drug: no circulating parent compound
– presence in plasma of SA only, and no other
metabolic species found
– slow NO release.
We can postulate that the drug, which is stable
in the stomach under acidic conditions [11], is
largely absorbed by the small intestine, reaches
the liver, where undergoes substantial first pass
effect to be metabolised to SA and HBN; this last
to the thioether adduct which in vivo will follow
the typical metabolic pathway of glutathione con-
jugates (degradation to mercapturic acid deriva-
tives and excretion in urines) and in lesser extent
to HBA which will undergo rapid conjugation
with glucuronic/sulphuric acid (urines). The mas-
sive HBN sequestration by the liver in the form of
the thioether adduct results in a spreading of
Table 2
HBN metabolization by rat liver cytosol: relative amounts of
the conjugated product formed
Incubation Conjugate product formation
time/conditions
Relative% nmoles/g tissue
32.72.4 96.77.1105 000×g (5 min)
105 000×g (10 min) 175.414.559.34.9
78.56.8 232.220.2105 000×g (15 min)
100105 000×g (30 min) 295.824.4
–105 000×g inactivated –
by heating at 100 °C
105 000×g inactivated ––
by heating at
100 °C+5 mM GSH
105 000×g (30 min) ––
+5 mM NEM
–105 000×g (30 min) –
+2 mM SBP
105 000×g fraction equivalent to 2.5 g fresh tissue was incu-
bated with 250 g HBN in the presence or in the absence of
different activators/inhibitors. At different incubation times,
0.5 ml aliquots were extracted and processed as described in
Section 2 (final volume 2.0 ml). The formation of the conju-
gated product was determined by measuring the disappearance
of HBN. Each value is the meanS.D. of five independent
experiments. SBP, sulphobromophtalein; NEM, N-ethyl-
maleimide.
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nitrate species which can be excreted by the hepa-
tocyte as such or undergo a step-by-step conversion
by liver reductases to bioactive NO. This can
explain the limited and slow release of NO from
NCX4016 observed in vivo: as recently evidenced
by us [10], the nitrosylhemoglobin [HbFe(II)NO]
complex, unequivocal marker of in vivo NO forma-
tion, is in fact detectable in blood of rats orally trea-
ted with NCX4016 (100, 200 mg/Kg) only 1 h after
drug administration and peaks between 4–6 h.
Table 3
Intra-assay precision and accuracy for determination of NCX4016 and its metabolites in rat liver S 9000×g fraction
Mean measured concentration (g/ml)Compound CV%Nominal concentration (g/ml) RE%
0.250 0.224 6.48 −10.0NCX4016
−1.484.052.4632.500
3.6810.08 +0.8010.00
49.75 2.4150.00 −0.50
0.250SA 0.237 7.80 −5.20
−1.085.202.4732.500
+1.202.7510.1210.00
50.00 49.40 2.40 −1.20
−4.004.950.4800.500HBN
+0.882.500 5.062.522
3.12 −2.009.8010.00
50.50 1.82 +1.0050.00
0.500 0.515 8.28 +3.00HBA
−1.203.152.4702.500
9.6510.00 1.80 −3.50
+0.702.1250.3550.00
Six replicates at each level. Coefficient of variance in percentage (CV%). Relative error (RE%).
Table 4
Inter-assay precision and accuracy for determination of NCX4016 and its metabolites in rat liver S 9000×g fraction
Compound Nominal concentration (g/ml) Mean measured concentration (g/ml) CV% RE%
0.237 7.82 −5.20NCX4016 0.250
2.548 5.452.500 +1.92
2.28 −1.609.84010.00
50.00 50.05 1.75 +0.10
0.250 0.260 5.32 +4.00SA
+1.203.272.5302.500
10.00 10.06 3.98 +0.60
50.00 49.88 2.72 −0.24
6.580.487 −2.600.500HBN
4.902.463 −1.482.500
9.9010.00 5.02 −1.00
−0.443.6549.7850.00
+1.407.140.5070.500HBA
5.21 −0.802.4802.500
10.00 10.07 2.48 +0.70
50.1550.00 1.95 +0.30
Six runs, duplicates at each level in each run over a period of 3 days. Coefficient of variance in percentage (CV%). Relative error
(RE%).
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